Research progress of biomarkers in early detection of chemotherapy-induced cardiotoxicity

被引：0
作者：
Wanli Gai
Jian An
Zhixin Wang
Xuebin Han
Jianhui Geng
Yunliang Liang
Yanqing Guo
机构：
[1] Shanxi Cardiovascular Hospital,Department of Cardiology
[2] First Hospital of Shanxi Medical University,Department of Cardiovascular Medicine
来源：
Heart Failure Reviews | 2021年 / 26卷
关键词：
Biomarker; Chemotherapy; Cardiotoxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With the advances of drug therapy, the prognosis of cancer patients has seen remarkable improvements, and cancer-related mortality has decreased significantly. However, the followed drug-related cardiotoxicity becomes a serious threat to patients’ living quality and survival rate. Cardiovascular toxicity associated with some chemotherapy drugs is reversible and dose-dependent. If early identification is possible, early cardiovascular protection measures or adjustment of chemotherapy regimens can be taken to improve the prognosis of patients. Therefore, early prevention and monitoring of chemotherapy-related cardiotoxicity are critical for cancer patients and survivors. Among them, biomarkers are an important method for the early identification of myocardial injury.
引用
收藏
页码：1195 / 1201
页数：6
相关论文
共 258 条
  • [1] Truong J(2014)Chemotherapy-induced cardiotoxicity: detection, prevention, and management.[J] Can J Cardiol 30 869-878
  • [2] Yan AT(2008)Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study.[J] J Natl Cancer Inst 100 1368-1379
  • [3] Cramarossa G(2014)Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J] Eur Heart J Cardiovasc Imaging 15 1063-1093
  • [4] Chan KK(2010)Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy[J] J Am Coll Cardiol 55 213-220
  • [5] Mertens AC(2008)Cardiac toxicity in breast cancer survivors: review of potential cardiac problems[J] Clin Cancer Res 14 14-24
  • [6] Liu Q(2002)Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients[J] Ann Oncol 13 699-709
  • [7] Neglia JP(2014)Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab[J] J Am Coll Cardiol 63 809-816
  • [8] Wasilewski K(2017)Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2–positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy[J] J Clin Oncol 35 878-884
  • [9] Leisenring W(2018)Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: a narrative review[J] Biomed Pharmacother 107 989-996
  • [10] Armstrong GT(2014)Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.[J] Clin Cancer Res 20 6314-6323
12345678910